Immunocore Holdings (IMCR) Enterprise Value (2019 - 2026)

Immunocore Holdings (IMCR) has reported Enterprise Value for 8 consecutive years, with -$844.9 million the latest figure, recorded in Q1 2026.

• Quarterly Enterprise Value fell 0.94% year-over-year to -$844.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$844.9 million (down 0.94% YoY) and the FY2025 annual result came in at -$864.2 million, down 5.34% from the prior year.
• Enterprise Value rose to -$844.9 million in Q1 2026 per IMCR's latest filing, from -$864.2 million in the prior quarter.
• Over the last five years, Enterprise Value for IMCR reached as high as -$262.0 million in Q2 2022 and fell as low as -$901.3 million in Q3 2024.
• A 5-year average of -$690.5 million and a median of -$834.9 million in 2024 frame the typical range for Enterprise Value.
• Annual changes were most pronounced in 2024 — Enterprise Value slumped 100.66% — and 2025, when it increased 0.99%.
• Year by year, Enterprise Value stood at -$390.0 million in 2022, then decreased by 13.48% to -$442.6 million in 2023, then tumbled by 85.34% to -$820.4 million in 2024, then fell by 5.34% to -$864.2 million in 2025, then rose by 2.23% to -$844.9 million in 2026.
• According to Business Quant data, Enterprise Value over the past three periods registered -$844.9 million, -$864.2 million, and -$892.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.